Cargando…
WIN site inhibition disrupts a subset of WDR5 function
WDR5 nucleates the assembly of histone-modifying complexes and acts outside this context in a range of chromatin-centric processes. WDR5 is also a prominent target for pharmacological inhibition in cancer. Small-molecule degraders of WDR5 have been described, but most drug discovery efforts center o...
Autores principales: | Siladi, Andrew J., Wang, Jing, Florian, Andrea C., Thomas, Lance R., Creighton, Joy H., Matlock, Brittany K., Flaherty, David K., Lorey, Shelly L., Howard, Gregory C., Fesik, Stephen W., Weissmiller, April M., Liu, Qi, Tansey, William P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813994/ https://www.ncbi.nlm.nih.gov/pubmed/35115608 http://dx.doi.org/10.1038/s41598-022-05947-9 |
Ejemplares similares
-
Targeting WDR5: A WINning Anti-Cancer Strategy?
por: Aho, Erin R, et al.
Publicado: (2019) -
Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance
por: Thomas, Lance R., et al.
Publicado: (2019) -
Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells
por: Florian, Andrea C, et al.
Publicado: (2022) -
WDR5 is a conserved regulator of protein synthesis gene expression
por: Bryan, Audra F, et al.
Publicado: (2020) -
Impact of WIN site inhibitor on the WDR5 interactome
por: Guarnaccia, Alissa D., et al.
Publicado: (2021)